Baseline clinical HIV genotypes are a valid measure of transmitted drug resistance within the treatment-naive population

Journal of Acquired Immune Deficiency Syndromes

Volumn 64, Issue 5, 2013, Pages 443-447

  Ragonnet Cronin, Manon ^a   Lee, Bonita E ^b   Plitt, Sabrina S ^c   Zahariadis, George ^d,e   Merks, Harriet ^a   Sandstrom, Paul A ^a   Brooks, James I ^a,e,f  

^a PUBLIC HEALTH AGENCY OF CANADA   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

^c PUBLIC HEALTH AGENCY OF CANADA   (Canada)

^d ALBERTA HEALTH SERVICES   (Canada)

^e UNIVERSITY OF WESTERN ONTARIO   (Canada)

^f UNIVERSITY OF OTTAWA   (Canada)

Author keywords

clinical genotyping; drug resistance surveillance; genotyping; transmitted drug resistance

Indexed keywords

ARTICLE; CANADA; CONTROLLED STUDY; DISEASE SURVEILLANCE; ENZYME IMMUNOASSAY; GENETIC DISTANCE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; PHYSICAL SENSITIVITY; PRIORITY JOURNAL; TRANSMITTED DRUG RESISTANCE; ANTIVIRAL RESISTANCE; EPIDEMIOLOGICAL MONITORING; GENETICS; ISOLATION AND PURIFICATION; TRANSMISSION; VIROLOGY; DISEASE TRANSMISSION;

ALBERTA; DRUG RESISTANCE, VIRAL; EPIDEMIOLOGICAL MONITORING; GENOTYPE; HIV; HIV INFECTIONS; HUMANS;

EID: 84892567259     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3182a4b991     Document Type: Article

References (40)

1. Abegaz WE, Grossman Z, Wolday D, et al. Threshold survey evaluating transmitted HIV drug resistance among public antenatal clinic clients in Addis Ababa, Ethiopia. Antivir Ther. 2008;13(suppl 2):89-94
2. Bennett DE, Bertagnolio S, Sutherland D, et al. The World Health Organization's global strategy for prevention and assessment of HIV drug resistance. Antivir Ther. 2008;13(suppl 2):1-13
3. Nguyen HT, Duc NB, Shrivastava R, et al. HIV drug resistance threshold survey using specimens from voluntary counselling and testing sites in Hanoi, Vietnam. Antivir Ther. 2008;13(suppl 2):115-121
4. Payne BA, Nsutebu EF, Hunter ER, et al. Low prevalence of transmitted antiretroviral drug resistance in a large UK HIV-1 cohort. J Antimicrob Chemother. 2008;62:464-468
5. Pillay D. Current patterns in the epidemiology of primary HIV drug resistance in North America and Europe. Antivir Ther. 2004;9:695-702
6. Yerly S, Jost S, Telenti A, et al. Infrequent transmission of HIV-1 drugresistant variants. Antivir Ther. 2004;9:375-384
7. Leigh Brown AJ, Frost SD, Mathews WC, et al. Transmission fitness of drug-resistant human immunodeficiency virus and the prevalence of resistance in the antiretroviral-treated population. J Infect Dis. 2003; 187:683-686
8. Jayaraman GC, Gleeson T, Rekart ML, et al. Prevalence and determinants of HIV-1 subtypes in Canada: Enhancing routinely collected information through the Canadian HIV Strain and Drug Resistance Surveillance Program. Can Commun Dis Rep. 2003;29:29-36
9. Hirsch MS, Gunthard HF, Schapiro JM, et al. Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. Clin Infect Dis. 2008;47:266-285
10. Johnson JA, Li JF, Wei X, et al. Minority HIV-1 drug resistance mutations are present in antiretroviral treatment-naive populations and associate with reduced treatment efficacy. PLoS Med. 2008;5:e158
11. Little SJ. Is transmitted drug resistance in HIV on the rise? It seems so. BMJ. 2001;322:1074-1075
12. Little SJ, Frost SD, Wong JK, et al. Persistence of transmitted drug resistance among subjects with primary human immunodeficiency virus infection. J Virol. 2008;82:5510-5518
13. Gazzard BG. British HIV Association Guidelines for the treatment of HIV-1- infected adults with antiretroviral therapy 2008. HIV Med. 2008;9:563-608
14. The EuroGuidelines Group for HIV Resistance. Clinical and laboratory guidelines for the use of HIV-1 drug resistance testing as part of treatment management: Recommendations for the European setting. AIDS. 2001;15:309-320
15. Ragonnet-Cronin M, Ofner-Agostini M, Merks H, et al. Longitudinal phylogenetic surveillance identifies distinct patterns of cluster dynamics. J Acquir Immune Defic Syndr. 2010;55:102-108
16. Parekh BS, Kennedy MS, Dobbs T, et al. Quantitative detection of increasing HIV type 1 antibodies after seroconversion: A simple assay for detecting recent HIV infection and estimating incidence. AIDS Res Hum Retroviruses. 2002;18:295-307
17. Woods CK, Brumme CJ, Liu TF, et al. Automating HIV drug resistance genotyping with RECall, a freely accessible sequence analysis tool. J Clin Microbiol. 2012;50:1936-1942
18. Posada D. jModelTest: Phylogenetic model averaging. Mol Biol Evol. 2008;25:1253-1256
19. Price MN, Dehal PS, Arkin AP. FastTree 2 - Approximately maximumlikelihood trees for large alignments. PLoS One. 2010;5:e9490
20. Gifford RJ, Liu TF, Rhee SY, et al. The calibrated population resistance tool: Standardized genotypic estimation of transmitted HIV-1 drug resistance. Bioinformatics. 2009;25:1197-1198
21. Bennett DE, Camacho RJ, Otelea D, et al. Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update. PLoS One. 2009;4:e4724
22. Public Health Agency of Canada. HIV and AIDS in Canada. Surveillance Report to December 31, 2008. Ottawa, Canada: Surveillance and Risk Assessment Division, Centre for Communicable Diseases and Infection Control; 2009
23. Public Health Agency Canada. HIV/AIDS Epi Upates - July 2010. Surveillance and Risk Assessment Division, Centre for Communicable Diseases and Infection Control, Public Health Agency of Canada, 2010
24. Leigh Brown AJ, Lycett SJ, Weinert L, et al. Transmission network parameters estimated from HIV sequences for a nationwide epidemic. J Infect Dis. 2011;204:1463-1469
25. Kouyos RD, von WV, Yerly S, et al. Molecular epidemiology reveals long-term changes in HIV type 1 subtype B transmission in Switzerland. J Infect Dis. 2010;201:1488-1497
26. Prosperi MC, Ciccozzi M, Fanti I, et al. A novel methodology for largescale phylogeny partition. Nat Commun. 2011;2:321
27. Burchell AN, Bayoumi AM, Rourke SB, et al. Increase in transmitted HIV drug resistance among persons undergoing genotypic resistance testing in Ontario, Canada, 2002-09. J Antimicrob Chemother. 2012;67:2755-2765
28. Collins JA, Thompson MG, Paintsil E, et al. Competitive fitness of nevirapine-resistant human immunodeficiency virus type 1 mutants. J Virol. 2004;78:603-611
29. Dykes C, Wu H, Sims M, et al. Human immunodeficiency virus type 1
30. protease inhibitor drug-resistant mutants give discordant results when compared in single-cycle and multiple-cycle fitness assays. J Clin Microbiol. 2010;48:4035-4043
31. Barbour JD, Hecht FM, Wrin T, et al. Persistence of primary drug resistance among recently HIV-1 infected adults. AIDS. 2004;18:1683-1689
32. Ghosn J, Pellegrin I, Goujard C, et al. HIV-1 resistant strains acquired at the time of primary infection massively fuel the cellular reservoir and persist for lengthy periods of time. AIDS. 2006;20:159-170
33. Briones C, Perez-Olmeda M, Rodriguez C, et al. Primary genotypic and phenotypic HIV-1 drug resistance in recent seroconverters in Madrid. J Acquir Immune Defic Syndr. 2001;26:145-150
34. Little SJ, Holte S, Routy JP, et al. Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med. 2002;347:385-394
35. Jayaraman GC, Archibald CP, Kim J, et al. A population-based approach to determine the prevalence of transmitted drug-resistant HIV among recent versus established HIV infections: Results from the Canadian HIV strain and drug resistance surveillance program. J Acquir Immune Defic Syndr. 2006;42:86-90
36. Jain V, Sucupira MC, Bacchetti P, et al. Differential persistence of transmitted HIV-1 drug resistance mutation classes. J Infect Dis. 2011;203: 1174-1181
37. Gupta RK, Jordan MR, Sultan BJ, et al. Global trends in antiretroviral resistance in treatment-naive individuals with HIV after rollout of antiretroviral treatment in resource-limited settings: A global collaborative study and meta-regression analysis. Lancet. 2012;380:1250-1258
38. Jourdain G, Ngo-Giang-Huong N, Le Coeur S, et al. Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy. N Engl J Med. 2004;351:229-240
39. Gianella S, Richman DD. Minority variants of drug-resistant HIV. J Infect Dis. 2010;202:657-666
40. Public Health Agency Canada. HIV-1 Strain and Primary Drug Resistance in Canada: Surveillance Report to March 31, 2005. Surveillance and Risk Assessment Division, Centre for Communicable Diseases and Infection Control, Public Health Agency of Canada, 2006